Publication date: 1 February 2017
Source:Bioorganic & Medicinal Chemistry, Volume 25, Issue 3
Author(s): Yixing Sun, Weisi Xu, Ningning Fan, Xuefeng Sun, Xianling Ning, Liying Ma, Junyi Liu, Xiaowei Wang
Aiming at the limited effectiveness of current clinical therapeutic effect of AIDS, novel series of compounds bearing (E)-3,4-dihydroxystyryl sulfone (or sulfoxide) and anilide fragments were designed and synthesized as dual inhibitors of HIV-1 CCR5/IN. The biological results indicated that several target compounds showed inhibitory activity against HIV-1 Bal (R5) infection in TZM-bl cells. Besides targeting the chemokine receptor on the host cell surface, they also displayed binding affinities with HIV-1 integrase using the surface plasmon resonance (SPR) binding assays. Molecular docking studies have inferred the possible binding mode of target compounds against integrase. These data demonstrate that the structure of (E)-3,4-dihydroxystyryl sulfone and sulfoxide derivatives have the potential to derive potent dual inhibitors of HIV-1 Integrase and CCR5.
Graphical abstract
http://ift.tt/2kLiX9o
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου